董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erick J. Lucera | 男 | Director | 58 | 1.70万美元 | 未持股 | 2026-01-30 |
| Steven A. Lisi | 男 | Chairman of the Board and Chief Executive Officer,Director | 55 | 82.11万美元 | 未持股 | 2026-01-30 |
| William Forbes | 男 | Director | 64 | 1.70万美元 | 未持股 | 2026-01-30 |
| Yoori Lee | 女 | Director | 53 | 1.70万美元 | 未持股 | 2026-01-30 |
| Robert S. Goodman | 男 | Director | 61 | 未披露 | 未持股 | 2026-01-30 |
| Robert F. Carey | 男 | Director | 67 | 1.70万美元 | 未持股 | 2026-01-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven A. Lisi | 男 | Chairman of the Board and Chief Executive Officer,Director | 55 | 82.11万美元 | 未持股 | 2026-01-30 |
| Michael Gaul | 男 | Chief Operating Officer | 72 | 46.49万美元 | 未持股 | 2026-01-30 |
| Denton Dewrell | 男 | Principal Accounting Officer and Principal Financial Officer | 40 | 未披露 | 未持股 | 2026-01-30 |
董事简历
中英对照 | 中文 | 英文- Erick J. Lucera
-
Erick J. Lucera于2017年8月加入Beyond Air, Inc.董事会。他被任命为AVEO Oncology（Nasdaq：AVEO）的首席财务官，AVEO Oncology是一家在纳斯达克上市的生物制药公司，2020年专注于满足肿瘤和其他未满足的医疗需求的靶向药物。2016年至2019年，Lucera先生担任Valeritas Holdings, Inc.（一家在美国纳斯达克上市的商业公司，开发糖尿病新技术）的首席财务官。Lucera先生于2015年至2016年担任Viventia Bio首席财务官、财务主管兼秘书。2012年至2015年，他在兽用生物制药公司Aratana Therapeutics担任企业发展副总裁。在Aratana任职期间，他通过一系列收购和通过五次公开和非公开发行融资近2.5亿美元的授权交易，帮助扩大了公司的产品线。在担任医疗保健公司高管之前，Lucera先生在投资管理领域度过了超过15年，曾担任Eaton Vance公司的医疗保健分析师、Intrepid Capital的铁人三项生命科学基金的投资组合经理以及Independence Investments的医疗保健研究团队负责人。自2021年10月起，他担任Bone Biologics的董事会成员，Bone Biologics是一家在纳斯达克上市的生物制剂公司。他拥有哈佛大学公共卫生证书、波士顿学院量化金融硕士学位、印第安纳大学布卢明顿分校MBA学位和特拉华大学会计学学士学位。Lucera先生已获得CFA、CMA和注册会计师称号。
Erick J. Lucera joined Board of Directors in Augt 2017. He has served as the Chief Financial Officer of Dyne Therapeutics, Inc. (Nasdaq: DYN), a Nasdaq listed biotechnology company foced on developing targeted therapies for people living with genetically driven neuromcular disease, since March 31, 2025. He previoly served as Executive Vice President and Chief Financial Officer of Editas Medicine, Inc. (Nasdaq: EDIT), a Nasdaq listed clinical stage genome editing company, from May 2023 to March 2025. He was the Chief Financial Officer of AVEO Oncology (Nasdaq: AVEO), a Nasdaq traded biopharmaceutical company foced on targeted medicines for oncology and other unmet medical needs, from 2020 to 2023, when it was acquired by LG Chem, and was the Chief Financial Officer of Valeritas Holdings, Inc., a U.S. Nasdaq traded commercial stage company developing new technology for diabetes, from 2016 to 2019. Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of Viventia Bio from 2015 to 2016. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company's product pipeline through a series of acquisitions and in licensing transactions financed through five public and private offerings of nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He has served on the board of directors of SAB Biopharmapeutics, Inc., a Nasdaq traded clinical stage biopharmaceutical company, since April 2023. He holds a CPH from Harvard University, an MS in quantitative finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations. - Erick J. Lucera于2017年8月加入Beyond Air, Inc.董事会。他被任命为AVEO Oncology（Nasdaq：AVEO）的首席财务官，AVEO Oncology是一家在纳斯达克上市的生物制药公司，2020年专注于满足肿瘤和其他未满足的医疗需求的靶向药物。2016年至2019年，Lucera先生担任Valeritas Holdings, Inc.（一家在美国纳斯达克上市的商业公司，开发糖尿病新技术）的首席财务官。Lucera先生于2015年至2016年担任Viventia Bio首席财务官、财务主管兼秘书。2012年至2015年，他在兽用生物制药公司Aratana Therapeutics担任企业发展副总裁。在Aratana任职期间，他通过一系列收购和通过五次公开和非公开发行融资近2.5亿美元的授权交易，帮助扩大了公司的产品线。在担任医疗保健公司高管之前，Lucera先生在投资管理领域度过了超过15年，曾担任Eaton Vance公司的医疗保健分析师、Intrepid Capital的铁人三项生命科学基金的投资组合经理以及Independence Investments的医疗保健研究团队负责人。自2021年10月起，他担任Bone Biologics的董事会成员，Bone Biologics是一家在纳斯达克上市的生物制剂公司。他拥有哈佛大学公共卫生证书、波士顿学院量化金融硕士学位、印第安纳大学布卢明顿分校MBA学位和特拉华大学会计学学士学位。Lucera先生已获得CFA、CMA和注册会计师称号。
- Erick J. Lucera joined Board of Directors in Augt 2017. He has served as the Chief Financial Officer of Dyne Therapeutics, Inc. (Nasdaq: DYN), a Nasdaq listed biotechnology company foced on developing targeted therapies for people living with genetically driven neuromcular disease, since March 31, 2025. He previoly served as Executive Vice President and Chief Financial Officer of Editas Medicine, Inc. (Nasdaq: EDIT), a Nasdaq listed clinical stage genome editing company, from May 2023 to March 2025. He was the Chief Financial Officer of AVEO Oncology (Nasdaq: AVEO), a Nasdaq traded biopharmaceutical company foced on targeted medicines for oncology and other unmet medical needs, from 2020 to 2023, when it was acquired by LG Chem, and was the Chief Financial Officer of Valeritas Holdings, Inc., a U.S. Nasdaq traded commercial stage company developing new technology for diabetes, from 2016 to 2019. Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of Viventia Bio from 2015 to 2016. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company's product pipeline through a series of acquisitions and in licensing transactions financed through five public and private offerings of nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He has served on the board of directors of SAB Biopharmapeutics, Inc., a Nasdaq traded clinical stage biopharmaceutical company, since April 2023. He holds a CPH from Harvard University, an MS in quantitative finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations.
- Steven A. Lisi
-
StevenA.Lisi自2017年1月13日起担任我们的董事会成员，并自2016年6月起担任我们的全资子公司AIT Ltd.的董事会成员。Lisi先生自2017年6月14日起担任我们的首席执行官。Lisi先生以前是Avadel Technologies AVDL的业务和企业发展高级副总裁，他在该公司的重组中发挥了重要作用，并在三年内将其企业价值从1亿美元转变为10亿美元。Lisi先生筹集了1.21亿美元的股权，领导了Flamel&8217；的合同制造设施的出售，理顺了产品线，重新调整了业务开发工作的重点，转变了投资者基础，并在爱尔兰建立了Flamel&8217；的存在。在Flamel任职之前，Lisi先生在Mehta和Isaly（现为OrbiMed）、SAC Capital（投资组合经理）、Millennium Partners（投资组合经理）、Panacea Asset Management（共同所有人）和Deerfield Management（合伙人）的全球梦百合公司投资了18年。Lisi先生担任Mico Innovations的董事会成员，这是一家下一代冠状动脉和神经血管支架公司。Lisi先生在佩珀代因大学（Pepperdine University）获得国际商务硕士学位。
Steven A. Lisi has served on Board of Directors since January 13, 2017, and has served on the board of directors of BA Ltd. ("BA"), wholly owned subsidiary, since June 2016. Mr. Lisi has served as Chief Executive Officer since June 14, 2017. Mr. Lisi was previoly Senior Vice President of Biness and Corporate Development at Avadel Technologies (AVDL), where he was instrumental in restructuring the company and transforming it from $100 million in enterprise value to $1 billion in three years. Mr. Lisi raised $121 million in equity, led the sale of Avadel's contract manufacturing facility, rationalized the product pipeline, refoced the biness development effort, transformed the investor base and established Avadel's presence in Ireland. Prior to his position with Avadel, Mr. Lisi spent 18 years investing in healthcare companies on a global basis at Mehta and Isaly (now OrbiMed), SAC Capital (portfolio manager), Millennium Partners (portfolio manager), Panacea Asset Management (co owner) and Deerfield Management (Partner). Mr. Lisi serves on the board of directors of Mico Innovations, a next generation coronary and neurovascular stent company. Mr. Lisi received his Master's in International Biness from Pepperdine University. - StevenA.Lisi自2017年1月13日起担任我们的董事会成员，并自2016年6月起担任我们的全资子公司AIT Ltd.的董事会成员。Lisi先生自2017年6月14日起担任我们的首席执行官。Lisi先生以前是Avadel Technologies AVDL的业务和企业发展高级副总裁，他在该公司的重组中发挥了重要作用，并在三年内将其企业价值从1亿美元转变为10亿美元。Lisi先生筹集了1.21亿美元的股权，领导了Flamel&8217；的合同制造设施的出售，理顺了产品线，重新调整了业务开发工作的重点，转变了投资者基础，并在爱尔兰建立了Flamel&8217；的存在。在Flamel任职之前，Lisi先生在Mehta和Isaly（现为OrbiMed）、SAC Capital（投资组合经理）、Millennium Partners（投资组合经理）、Panacea Asset Management（共同所有人）和Deerfield Management（合伙人）的全球梦百合公司投资了18年。Lisi先生担任Mico Innovations的董事会成员，这是一家下一代冠状动脉和神经血管支架公司。Lisi先生在佩珀代因大学（Pepperdine University）获得国际商务硕士学位。
- Steven A. Lisi has served on Board of Directors since January 13, 2017, and has served on the board of directors of BA Ltd. ("BA"), wholly owned subsidiary, since June 2016. Mr. Lisi has served as Chief Executive Officer since June 14, 2017. Mr. Lisi was previoly Senior Vice President of Biness and Corporate Development at Avadel Technologies (AVDL), where he was instrumental in restructuring the company and transforming it from $100 million in enterprise value to $1 billion in three years. Mr. Lisi raised $121 million in equity, led the sale of Avadel's contract manufacturing facility, rationalized the product pipeline, refoced the biness development effort, transformed the investor base and established Avadel's presence in Ireland. Prior to his position with Avadel, Mr. Lisi spent 18 years investing in healthcare companies on a global basis at Mehta and Isaly (now OrbiMed), SAC Capital (portfolio manager), Millennium Partners (portfolio manager), Panacea Asset Management (co owner) and Deerfield Management (Partner). Mr. Lisi serves on the board of directors of Mico Innovations, a next generation coronary and neurovascular stent company. Mr. Lisi received his Master's in International Biness from Pepperdine University.
- William Forbes
-
William Forbes于2018年8月加入我们的董事会。福布斯博士目前担任Vivelix Pharmaceuticals，Ltd.的创始人，总裁兼首席执行官，该公司是一家临床阶段的制药公司，自2016年以来专注于胃肠道疾病。创立Vivelix公司之前，Forbes博士曾任职Salix Pharmaceuticals公司，担任首席开发官，也曾担任医疗和研发主管。在加入Salix之前，Forbes博士在多家全球制药公司从事了15年的临床开发&法规事务和临床研究。
William Forbes joined Board of Directors in Augt 2018.Dr. Forbes has served as Chief Development Officer of Heron Therapeutics, Inc. (Nasdaq: HRTX), a Nasdaq traded commercial stage biotechnology company, since June 2023. Prior to joining Heron, he served as the Chief Development Officer of Trevi Therapeutics, a clinical stage pharmaceutical company foced on serio neurologically mediated diseases, from February 2021 to September 2022. Prior to Trevi, Dr. Forbes was at Salix Pharmaceuticals as the Chief Development Officer and also Head of Medical and R&D from January 2005 to June 2015. Prior to Salix, Dr. Forbes spent 15 years in Clinical Development & Regulatory Affairs and Clinical Research at a number of global pharmaceutical companies. - William Forbes于2018年8月加入我们的董事会。福布斯博士目前担任Vivelix Pharmaceuticals，Ltd.的创始人，总裁兼首席执行官，该公司是一家临床阶段的制药公司，自2016年以来专注于胃肠道疾病。创立Vivelix公司之前，Forbes博士曾任职Salix Pharmaceuticals公司，担任首席开发官，也曾担任医疗和研发主管。在加入Salix之前，Forbes博士在多家全球制药公司从事了15年的临床开发&法规事务和临床研究。
- William Forbes joined Board of Directors in Augt 2018.Dr. Forbes has served as Chief Development Officer of Heron Therapeutics, Inc. (Nasdaq: HRTX), a Nasdaq traded commercial stage biotechnology company, since June 2023. Prior to joining Heron, he served as the Chief Development Officer of Trevi Therapeutics, a clinical stage pharmaceutical company foced on serio neurologically mediated diseases, from February 2021 to September 2022. Prior to Trevi, Dr. Forbes was at Salix Pharmaceuticals as the Chief Development Officer and also Head of Medical and R&D from January 2005 to June 2015. Prior to Salix, Dr. Forbes spent 15 years in Clinical Development & Regulatory Affairs and Clinical Research at a number of global pharmaceutical companies.
- Yoori Lee
-
Yoori Lee于2018年1月加入我们的董事会。她自2013年起担任Trio Health Advisory Group，Inc.联合创始人和总裁。Trio Health的使命是通过协调所有患者护理利益相关者的努力来提高患者护理结果的护理质量。在加入Trio Health之前，Lee女士在Leerink Partners LLC（一家领先的梦百合投资银行）任职超过15年，在那里她担任董事总经理和MedaCorp Services的董事。此外，她还帮助建立了MedaCorp网络，这是一支专家队伍，包括临床医学、生物医学研究、监管事务、公共政策、梦百合管理和梦百合信息技术等不同领域的35000多名梦百合专业人员。
Yoori Lee joined Board of Directors in January 2018. She has served as Co founder and President of Trio Health Advisory Group, Inc. since 2013. Trio Health's mission is to improve the quality of care in patient outcomes through coordinating the efforts of all patient care stakeholders. Prior to Trio Health, Ms. Lee spent over 15 years at Leerink Partners LLC, a leading healthcare investment bank, where she was Managing Director, and Director of MEDACorp Services. Additionally, she helped found the MEDACorp network, a cadre of experts including more than 35,000 healthcare professionals in diverse areas of practice such as clinical medicine, biomedical research, regulatory affairs, public policy, healthcare administration and healthcare information technology. - Yoori Lee于2018年1月加入我们的董事会。她自2013年起担任Trio Health Advisory Group，Inc.联合创始人和总裁。Trio Health的使命是通过协调所有患者护理利益相关者的努力来提高患者护理结果的护理质量。在加入Trio Health之前，Lee女士在Leerink Partners LLC（一家领先的梦百合投资银行）任职超过15年，在那里她担任董事总经理和MedaCorp Services的董事。此外，她还帮助建立了MedaCorp网络，这是一支专家队伍，包括临床医学、生物医学研究、监管事务、公共政策、梦百合管理和梦百合信息技术等不同领域的35000多名梦百合专业人员。
- Yoori Lee joined Board of Directors in January 2018. She has served as Co founder and President of Trio Health Advisory Group, Inc. since 2013. Trio Health's mission is to improve the quality of care in patient outcomes through coordinating the efforts of all patient care stakeholders. Prior to Trio Health, Ms. Lee spent over 15 years at Leerink Partners LLC, a leading healthcare investment bank, where she was Managing Director, and Director of MEDACorp Services. Additionally, she helped found the MEDACorp network, a cadre of experts including more than 35,000 healthcare professionals in diverse areas of practice such as clinical medicine, biomedical research, regulatory affairs, public policy, healthcare administration and healthcare information technology.
- Robert S. Goodman
-
Robert S. Goodman，于2025年6月加入董事会。古德曼先生为《财富》50强企业带来了30多年的执行商业领导经验和跨越风险投资支持的新兴业务的成功。最近，他在开创性的健康科技公司Fourth Frontier的董事会任职，在那里他为该公司的510k FDA设备批准做出了贡献，并支持了成功的B轮融资。Goodman先生在2023-2024年期间担任制药公司WEP Clinical的首席商务官，帮助加速并提高了总合同价值和收入同比增长超过30%。古德曼先生曾在BioTelemetry担任部门总裁，并在2021年带领皇家飞利浦进行了一笔2.1亿美元的卖方交易。Goodman先生还拥有丰富的执行销售经验，曾于2008-2017年担任Cardiocore（后被BioTelemetry收购）的销售与营销高级副总裁，并于2007-2008年担任赛默飞世尔的高级董事、销售与营销主管。
Robert S. Goodman joined Board of Directors in June 2025. Most recently, he served on the Board of Directors of Fth Frontier, a pioneering health tech company, where he contributed to the company's 510k FDA device approval and supported a successful Series B financing. Mr. Goodman served as the Chief Commercial Officer for pharmaceutical company P Clinical from 2023 2024, where he helped accelerate and increase total contract values and revenue growth by over 30% YOY. Mr. Goodman served as Division President at BioTelemetry, where he led a $2.1B sell side transaction to Royal Philips in 2021. Mr. Goodman also has extensive executive sales experience, serving as SVP, Sales & Marketing of Cardiocore (later acquired by BioTelemetry) from 2008 2017 and as Thermo Fisher's Senior Director, Head of Sales & Marketing from 2007 2008. - Robert S. Goodman，于2025年6月加入董事会。古德曼先生为《财富》50强企业带来了30多年的执行商业领导经验和跨越风险投资支持的新兴业务的成功。最近，他在开创性的健康科技公司Fourth Frontier的董事会任职，在那里他为该公司的510k FDA设备批准做出了贡献，并支持了成功的B轮融资。Goodman先生在2023-2024年期间担任制药公司WEP Clinical的首席商务官，帮助加速并提高了总合同价值和收入同比增长超过30%。古德曼先生曾在BioTelemetry担任部门总裁，并在2021年带领皇家飞利浦进行了一笔2.1亿美元的卖方交易。Goodman先生还拥有丰富的执行销售经验，曾于2008-2017年担任Cardiocore（后被BioTelemetry收购）的销售与营销高级副总裁，并于2007-2008年担任赛默飞世尔的高级董事、销售与营销主管。
- Robert S. Goodman joined Board of Directors in June 2025. Most recently, he served on the Board of Directors of Fth Frontier, a pioneering health tech company, where he contributed to the company's 510k FDA device approval and supported a successful Series B financing. Mr. Goodman served as the Chief Commercial Officer for pharmaceutical company P Clinical from 2023 2024, where he helped accelerate and increase total contract values and revenue growth by over 30% YOY. Mr. Goodman served as Division President at BioTelemetry, where he led a $2.1B sell side transaction to Royal Philips in 2021. Mr. Goodman also has extensive executive sales experience, serving as SVP, Sales & Marketing of Cardiocore (later acquired by BioTelemetry) from 2008 2017 and as Thermo Fisher's Senior Director, Head of Sales & Marketing from 2007 2008.
- Robert F. Carey
-
Robert F. Carey于2019年2月加入Beyond Air，Inc.董事会。他帮助生物技术和专业制药公司通过首次公开发行、后续发行、债务发行和私募融资筹集了超过100亿美元。他曾担任并购和战略联盟交易的财务顾问，总交易价值超过100亿美元。Carey先生共同创立了ACELYRIN，Inc.，并担任该公司的总裁兼首席运营官，该公司是一家生物制药公司，将投资、开发和商业化改变生命的药物疗法。Carey先生曾于2014年3月至2019年9月担任Horizon Therapeutics plc的执行副总裁兼首席业务官，在此期间，Horizon therrapeutics斥资超过35亿美元收购或许可了8种商业产品和3种正在开发的产品，净销售额从2013年的7400万美元增长至2018年的约12亿美元，复合年增长率为75%。在Horizon之前，他曾在JMP证券担任常务董事兼生命科学投资银行集团负责人超过11年。Carey先生还是Dresdner Kleinwort Wasserstein和Vector Securities医疗集团的董事总经理。他在圣母大学获得会计学学士学位。Carey先生目前担任Sangamo Therapeutics，Inc.股份有限公司和Hawthorne Race Course，Inc.股份有限公司的董事会成员，并曾于2020年7月至2021年2月担任双子治疗学股份有限公司的Disk Medicine，Inc.董事会成员。
Robert F. Carey joined Board of Directors in February 2019. He has an extensive track record of accomplishment within the biopharmaceutical and healthcare investment banking indtry. He has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow on offerings, debt offerings, and private placements. He has served as a financial advisor on mergers, acquisitions, and strategic alliance transactions with a total deal value of more than $10 billion. Mr. Carey is a co founder and from July 2020 until December 2022 was President of ACELYRIN, INC., a biopharmaceutical company developing life changing drug therapies.Mr. Carey previoly served as Executive Vice President and Chief Biness Officer at Horizon Therapeutics plc from March 2014 to September 2019, during which Horizon Therapeutics deployed in excess of $3.5 billion to acquire or license eight commercial products and three products in development and grew net sales from $74 million in 2013 to approximately $1.2 billion in 2018, a compound annual growth rate of 75%. Before Horizon, he spent more than 11 years as Managing Director and Head of the Life Sciences Investment Banking Group at JMP Securities. Mr. Carey was also Managing Director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. He received his B.B.A. in Accounting from the University of Notre Dame. Mr. Carey currently serves on the Board of Beyond Cancer Ltd. and Sangamo Therapeutics, Inc. - Robert F. Carey于2019年2月加入Beyond Air，Inc.董事会。他帮助生物技术和专业制药公司通过首次公开发行、后续发行、债务发行和私募融资筹集了超过100亿美元。他曾担任并购和战略联盟交易的财务顾问，总交易价值超过100亿美元。Carey先生共同创立了ACELYRIN，Inc.，并担任该公司的总裁兼首席运营官，该公司是一家生物制药公司，将投资、开发和商业化改变生命的药物疗法。Carey先生曾于2014年3月至2019年9月担任Horizon Therapeutics plc的执行副总裁兼首席业务官，在此期间，Horizon therrapeutics斥资超过35亿美元收购或许可了8种商业产品和3种正在开发的产品，净销售额从2013年的7400万美元增长至2018年的约12亿美元，复合年增长率为75%。在Horizon之前，他曾在JMP证券担任常务董事兼生命科学投资银行集团负责人超过11年。Carey先生还是Dresdner Kleinwort Wasserstein和Vector Securities医疗集团的董事总经理。他在圣母大学获得会计学学士学位。Carey先生目前担任Sangamo Therapeutics，Inc.股份有限公司和Hawthorne Race Course，Inc.股份有限公司的董事会成员，并曾于2020年7月至2021年2月担任双子治疗学股份有限公司的Disk Medicine，Inc.董事会成员。
- Robert F. Carey joined Board of Directors in February 2019. He has an extensive track record of accomplishment within the biopharmaceutical and healthcare investment banking indtry. He has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow on offerings, debt offerings, and private placements. He has served as a financial advisor on mergers, acquisitions, and strategic alliance transactions with a total deal value of more than $10 billion. Mr. Carey is a co founder and from July 2020 until December 2022 was President of ACELYRIN, INC., a biopharmaceutical company developing life changing drug therapies.Mr. Carey previoly served as Executive Vice President and Chief Biness Officer at Horizon Therapeutics plc from March 2014 to September 2019, during which Horizon Therapeutics deployed in excess of $3.5 billion to acquire or license eight commercial products and three products in development and grew net sales from $74 million in 2013 to approximately $1.2 billion in 2018, a compound annual growth rate of 75%. Before Horizon, he spent more than 11 years as Managing Director and Head of the Life Sciences Investment Banking Group at JMP Securities. Mr. Carey was also Managing Director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. He received his B.B.A. in Accounting from the University of Notre Dame. Mr. Carey currently serves on the Board of Beyond Cancer Ltd. and Sangamo Therapeutics, Inc.
高管简历
中英对照 | 中文 | 英文- Steven A. Lisi
StevenA.Lisi自2017年1月13日起担任我们的董事会成员，并自2016年6月起担任我们的全资子公司AIT Ltd.的董事会成员。Lisi先生自2017年6月14日起担任我们的首席执行官。Lisi先生以前是Avadel Technologies AVDL的业务和企业发展高级副总裁，他在该公司的重组中发挥了重要作用，并在三年内将其企业价值从1亿美元转变为10亿美元。Lisi先生筹集了1.21亿美元的股权，领导了Flamel&8217；的合同制造设施的出售，理顺了产品线，重新调整了业务开发工作的重点，转变了投资者基础，并在爱尔兰建立了Flamel&8217；的存在。在Flamel任职之前，Lisi先生在Mehta和Isaly（现为OrbiMed）、SAC Capital（投资组合经理）、Millennium Partners（投资组合经理）、Panacea Asset Management（共同所有人）和Deerfield Management（合伙人）的全球梦百合公司投资了18年。Lisi先生担任Mico Innovations的董事会成员，这是一家下一代冠状动脉和神经血管支架公司。Lisi先生在佩珀代因大学（Pepperdine University）获得国际商务硕士学位。
Steven A. Lisi has served on Board of Directors since January 13, 2017, and has served on the board of directors of BA Ltd. ("BA"), wholly owned subsidiary, since June 2016. Mr. Lisi has served as Chief Executive Officer since June 14, 2017. Mr. Lisi was previoly Senior Vice President of Biness and Corporate Development at Avadel Technologies (AVDL), where he was instrumental in restructuring the company and transforming it from $100 million in enterprise value to $1 billion in three years. Mr. Lisi raised $121 million in equity, led the sale of Avadel's contract manufacturing facility, rationalized the product pipeline, refoced the biness development effort, transformed the investor base and established Avadel's presence in Ireland. Prior to his position with Avadel, Mr. Lisi spent 18 years investing in healthcare companies on a global basis at Mehta and Isaly (now OrbiMed), SAC Capital (portfolio manager), Millennium Partners (portfolio manager), Panacea Asset Management (co owner) and Deerfield Management (Partner). Mr. Lisi serves on the board of directors of Mico Innovations, a next generation coronary and neurovascular stent company. Mr. Lisi received his Master's in International Biness from Pepperdine University.- StevenA.Lisi自2017年1月13日起担任我们的董事会成员，并自2016年6月起担任我们的全资子公司AIT Ltd.的董事会成员。Lisi先生自2017年6月14日起担任我们的首席执行官。Lisi先生以前是Avadel Technologies AVDL的业务和企业发展高级副总裁，他在该公司的重组中发挥了重要作用，并在三年内将其企业价值从1亿美元转变为10亿美元。Lisi先生筹集了1.21亿美元的股权，领导了Flamel&8217；的合同制造设施的出售，理顺了产品线，重新调整了业务开发工作的重点，转变了投资者基础，并在爱尔兰建立了Flamel&8217；的存在。在Flamel任职之前，Lisi先生在Mehta和Isaly（现为OrbiMed）、SAC Capital（投资组合经理）、Millennium Partners（投资组合经理）、Panacea Asset Management（共同所有人）和Deerfield Management（合伙人）的全球梦百合公司投资了18年。Lisi先生担任Mico Innovations的董事会成员，这是一家下一代冠状动脉和神经血管支架公司。Lisi先生在佩珀代因大学（Pepperdine University）获得国际商务硕士学位。
- Steven A. Lisi has served on Board of Directors since January 13, 2017, and has served on the board of directors of BA Ltd. ("BA"), wholly owned subsidiary, since June 2016. Mr. Lisi has served as Chief Executive Officer since June 14, 2017. Mr. Lisi was previoly Senior Vice President of Biness and Corporate Development at Avadel Technologies (AVDL), where he was instrumental in restructuring the company and transforming it from $100 million in enterprise value to $1 billion in three years. Mr. Lisi raised $121 million in equity, led the sale of Avadel's contract manufacturing facility, rationalized the product pipeline, refoced the biness development effort, transformed the investor base and established Avadel's presence in Ireland. Prior to his position with Avadel, Mr. Lisi spent 18 years investing in healthcare companies on a global basis at Mehta and Isaly (now OrbiMed), SAC Capital (portfolio manager), Millennium Partners (portfolio manager), Panacea Asset Management (co owner) and Deerfield Management (Partner). Mr. Lisi serves on the board of directors of Mico Innovations, a next generation coronary and neurovascular stent company. Mr. Lisi received his Master's in International Biness from Pepperdine University.
- Michael Gaul
Michael Gaul自2022年7月1日起担任Beyond Air, Inc.首席运营官。高卢先生于2020年5月加入公司，担任运营高级副总裁，这一头衔一直保持到2022年6月。高卢先生曾在运营、销售和营销、供应链、分销、质量、监管、人力资源和财务等领域领导团队。他曾在美国和亚洲的多家工厂担任过P & L方面的经验，包括2011年9月至2020年2月在海事防务承包商Sparton Corporation（制造与设计服务业务部门集团副总裁；医疗业务部门集团副总裁）任职，2005年6月至2011年2月在商业认可的全人工心脏制造商和供应商SynCardia Systems（COO；运营副总裁）任职，2003年9月至2005年2月在医疗器械公司Ventana Medical Systems（现名Roche Tissue Diagnostics）（副总裁兼运营总经理）任职，以及Robotic Vision Systems，Inc.（总经理，先锋部；系统部运营副总裁），机器视觉系统制造商，1997年9月至2003年6月。他目前还担任俄亥俄州生命科学协会的董事会成员，以支持和促进俄亥俄州的生物科学产业。高卢先生拥有特拉华谷大学工商管理学士学位和佛罗里达理工学院工商管理硕士学位。
Michael Gaul has been Chief Operating Officer since July 1, 2022. Mr. Gaul joined the Company in May 2020 as Senior VP, Operations, a title he held until June 2022. Mr. Gaul has led teams in operations, sales and marketing, supply chain, distribution, quality, regulatory, human resces, and finance. He has had P&L experience with multi plant responsibility in both the and Asia, including roles with Sparton Corporation (Group VP, Manufacturing & Design Services Biness Unit; Group VP, Medical Biness Unit), a defense contractor for maritime defense, from September 2011 to February 2020, SynCardia Systems (COO; VP Operations), a manufacturer and provider of the commercially approved Total Artificial Heart, from June 2005 to February 2011, Ventana Medical Systems (now known as Roche Tissue Diagnostics) (VP & General Manager, Operations), a medical device company, from September 2003 to April 2005, and Robotic Vision Systems, Inc. (General Manager, Vanguard Division; VP Operations, Systemation Division), a maker of machine vision systems, from September 1997 to June 2003. He also currently serves on the Board of Directors of BioOhio to support and promote Ohio's bioscience indtry. Mr. Gaul has a BS, Biness Administration from Delaware Valley University, and an MBA from Florida Institute of Technology.- Michael Gaul自2022年7月1日起担任Beyond Air, Inc.首席运营官。高卢先生于2020年5月加入公司，担任运营高级副总裁，这一头衔一直保持到2022年6月。高卢先生曾在运营、销售和营销、供应链、分销、质量、监管、人力资源和财务等领域领导团队。他曾在美国和亚洲的多家工厂担任过P & L方面的经验，包括2011年9月至2020年2月在海事防务承包商Sparton Corporation（制造与设计服务业务部门集团副总裁；医疗业务部门集团副总裁）任职，2005年6月至2011年2月在商业认可的全人工心脏制造商和供应商SynCardia Systems（COO；运营副总裁）任职，2003年9月至2005年2月在医疗器械公司Ventana Medical Systems（现名Roche Tissue Diagnostics）（副总裁兼运营总经理）任职，以及Robotic Vision Systems，Inc.（总经理，先锋部；系统部运营副总裁），机器视觉系统制造商，1997年9月至2003年6月。他目前还担任俄亥俄州生命科学协会的董事会成员，以支持和促进俄亥俄州的生物科学产业。高卢先生拥有特拉华谷大学工商管理学士学位和佛罗里达理工学院工商管理硕士学位。
- Michael Gaul has been Chief Operating Officer since July 1, 2022. Mr. Gaul joined the Company in May 2020 as Senior VP, Operations, a title he held until June 2022. Mr. Gaul has led teams in operations, sales and marketing, supply chain, distribution, quality, regulatory, human resces, and finance. He has had P&L experience with multi plant responsibility in both the and Asia, including roles with Sparton Corporation (Group VP, Manufacturing & Design Services Biness Unit; Group VP, Medical Biness Unit), a defense contractor for maritime defense, from September 2011 to February 2020, SynCardia Systems (COO; VP Operations), a manufacturer and provider of the commercially approved Total Artificial Heart, from June 2005 to February 2011, Ventana Medical Systems (now known as Roche Tissue Diagnostics) (VP & General Manager, Operations), a medical device company, from September 2003 to April 2005, and Robotic Vision Systems, Inc. (General Manager, Vanguard Division; VP Operations, Systemation Division), a maker of machine vision systems, from September 1997 to June 2003. He also currently serves on the Board of Directors of BioOhio to support and promote Ohio's bioscience indtry. Mr. Gaul has a BS, Biness Administration from Delaware Valley University, and an MBA from Florida Institute of Technology.
- Denton Dewrell
Denton Dewrell，自2025年4月起担任公司全球财务总监。在担任这一职务之前，他于2024年8月开始担任公司的美国财务总监，并自2023年8月起担任公司控股子公司Beyond Cancer Ltd.（“Beyond Cancer”）的财务负责人和财务总监。在加入公司之前，Dewrell先生于2021年7月至2023年8月在搬迁和房地产技术公司Updater Inc.担任副总裁兼公司财务总监。在其职业生涯的早期，Dewrell先生曾在安永会计师事务所从事公共会计工作十多年，2011年3月至2021年6月，他在审计和鉴证业务中担任的职务责任越来越大。Dewrell先生拥有佛罗里达大学会计学硕士学位和会计学学士学位，是佛罗里达州和乔治亚州的注册会计师。
Denton Dewrell was appointed as the Principal Financial Officer and Principal Accounting Officer of Company on December 8, 2025. Mr. Dewrell has served as the Global Controller of the Company since April 2025. Prior to this role, he served as the Company's U.S. Controller beginning in Augt 2024 and as Head of Finance and Controller of Beyond Cancer Ltd., since Augt 2023. Prior to joining the Company, Mr. Dewrell served as Vice President, Corporate Controller at Updater Inc., a relocation and real estate technology company, from July 2021 to Augt 2023. Earlier in his career, Mr. Dewrell spent more than ten years in public accounting at Ernst & Young LLP, where he held positions of increasing responsibility in the audit and assurance practice from March 2011 to June 2021. Mr. Dewrell holds a Master of Accounting and a Bachelor of Science in Accounting from the University of Florida and is a certified public accountant in Florida and Georgia.- Denton Dewrell，自2025年4月起担任公司全球财务总监。在担任这一职务之前，他于2024年8月开始担任公司的美国财务总监，并自2023年8月起担任公司控股子公司Beyond Cancer Ltd.（“Beyond Cancer”）的财务负责人和财务总监。在加入公司之前，Dewrell先生于2021年7月至2023年8月在搬迁和房地产技术公司Updater Inc.担任副总裁兼公司财务总监。在其职业生涯的早期，Dewrell先生曾在安永会计师事务所从事公共会计工作十多年，2011年3月至2021年6月，他在审计和鉴证业务中担任的职务责任越来越大。Dewrell先生拥有佛罗里达大学会计学硕士学位和会计学学士学位，是佛罗里达州和乔治亚州的注册会计师。
- Denton Dewrell was appointed as the Principal Financial Officer and Principal Accounting Officer of Company on December 8, 2025. Mr. Dewrell has served as the Global Controller of the Company since April 2025. Prior to this role, he served as the Company's U.S. Controller beginning in Augt 2024 and as Head of Finance and Controller of Beyond Cancer Ltd., since Augt 2023. Prior to joining the Company, Mr. Dewrell served as Vice President, Corporate Controller at Updater Inc., a relocation and real estate technology company, from July 2021 to Augt 2023. Earlier in his career, Mr. Dewrell spent more than ten years in public accounting at Ernst & Young LLP, where he held positions of increasing responsibility in the audit and assurance practice from March 2011 to June 2021. Mr. Dewrell holds a Master of Accounting and a Bachelor of Science in Accounting from the University of Florida and is a certified public accountant in Florida and Georgia.